Intestinal and mucosal immune cells

Intestinal and mucosal immune cells constitute the largest and most complex component of the body's immune system, primarily organized within the gut-associated lymphoid tissue (GALT) [StatPearls]. This heterogeneous population includes specialized T cells, B cells (notably IgA-secreting plasma cells), dendritic cells, and macrophages, which reside in the lamina propria and epithelial layer of the gastrointestinal tract [Nature Reviews Immunology]. Their primary biological role is to maintain mucosal homeostasis by providing a robust defense against enteric pathogens while simultaneously ensuring immune tolerance toward harmless dietary antigens and commensal microbiota [NIH]. In pathological conditions such as inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, these cells become dysregulated, leading to the chronic production of pro-inflammatory cytokines and tissue destruction [PubMed]. While the term refers to a broad cellular compartment rather than a single molecule, it is the primary site of action for numerous therapeutic agents that target specific molecular pathways within these cells, such as integrins, cytokines, and intracellular kinases [NCBI]. Modulating the activity and trafficking of these cells is a cornerstone of modern treatment strategies for autoimmune and inflammatory disorders of the gut [Journal of Crohn's and Colitis].

Other names

Gut-associated lymphoid tissue (GALT)Mucosa-associated lymphoid tissue (MALT)Lamina propria lymphocytes (LPLs)Intraepithelial lymphocytes (IELs)Peyer's patchesMesenteric lymph nodes

Therapeutic agents modulate these cells by inhibiting lymphocyte trafficking to the intestinal mucosa (e.g., integrin antagonism), neutralizing pro-inflammatory cytokines produced by these cells (e.g., TNF or IL-12/23 inhibition), or blocking intracellular signaling pathways (e.g., JAK inhibition) to suppress immune activation.